Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Journal of Thrombosis and Haemostasis

Volumn 18, Issue 4, 2020, Pages 844-847

  Tang, Ning ^a   Li, Dengju ^a   Wang, Xiong ^a   Sun, Ziyong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

coagulation parameter; D dimer; disseminated intravascular coagulation; fibrin degradation product; novel coronavirus pneumonia

Indexed keywords

D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

2019 NOVEL CORONAVIRUS; ADULT; ARTICLE; BLOOD CLOTTING; CHINA; CLINICAL FEATURE; CLINICAL OUTCOME; CONTROLLED STUDY; CORONAVIRINAE; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOLYSIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SURVIVOR; THROMBOPLASTIN TIME; ADOLESCENT; AGED; BETACORONAVIRUS; PANDEMIC; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; VERY ELDERLY; VIROLOGY; VIRUS PNEUMONIA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BETACORONAVIRUS; BLOOD COAGULATION; CHINA; CORONAVIRUS INFECTIONS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; PANDEMICS; PARTIAL THROMBOPLASTIN TIME; PNEUMONIA, VIRAL; PROTHROMBIN TIME; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85081755873     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.14768     Document Type: Article

References (10)

1. Zhu N, Zhang D, Wang W, et al. China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727-733.
2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507-513.
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506.
4. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. https://doi.org/10.1001/jama.2020.1585 [published online ahead of print].
5. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. Published January 28, 2020. Accessed January 31, 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
6. Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001; 86(5): 1327-1330.
7. Dempfle CE, Wurst M, Smolinski M, et al. Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost. 2004; 91(4): 812-818.
8. Kitchens CS. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Educ Program Am Soc Hematol. 2009; 2009(1): 240-246.
9. Gralinski LE, Bankhead A 3rd, Jeng S, et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio. 2013; 4(4): e00271-e313.
10. Berri F, Rimmelzwaan GF, Hanss M, et al. Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. PLoS Pathog. 2013; 9(3): e1003229.